These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

149 related items for PubMed ID: 39026312

  • 1. Clinical efficacy of thalidomide for various genotypes of beta thalassemia.
    Yang WJ, Kang QP, Zhou Q, Lin T, Gong XM, Huang CJ, Dou M, Lin Y.
    BMC Med Genomics; 2024 Jul 18; 17(1):191. PubMed ID: 39026312
    [Abstract] [Full Text] [Related]

  • 2. [Predictors of Hematologic Responses in Patients with Non-Transfusion-Dependent β-Thalassemia Receiving Thalidomide Therapy].
    Yang K, Yin XL, Liu XD, Hua F, Peng W, Li L, Chen K, Zhang J, Luo S, Xiao J.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Oct 18; 30(5):1519-1526. PubMed ID: 36208259
    [Abstract] [Full Text] [Related]

  • 3. Experience with combination of hydroxyurea and low-dose thalidomide in transfusion-dependent beta thalassemia patients.
    Bhurani D, Kapoor J, Yadav N, Khushoo V, Agrawal N, Ahmed R, Arora JS, Mehta P.
    Ann Hematol; 2021 Jun 18; 100(6):1417-1427. PubMed ID: 33811502
    [Abstract] [Full Text] [Related]

  • 4. Clinical trial on the effects of thalidomide on hemoglobin synthesis in patients with moderate thalassemia intermedia.
    Ren Q, Zhou YL, Wang L, Chen YS, Ma YN, Li PP, Yin XL.
    Ann Hematol; 2018 Oct 18; 97(10):1933-1939. PubMed ID: 29931453
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. The association of HBG2, BCL11A, and HBS1L-MYB polymorphisms to thalidomide response in Chinese β-thalassemia patients.
    Yang K, Wu Y, Ma Y, Xiao J, Zhou Y, Yin X.
    Blood Cells Mol Dis; 2020 Sep 18; 84():102442. PubMed ID: 32387854
    [Abstract] [Full Text] [Related]

  • 7. Response to hydroxycarbamide in pediatric β-thalassemia intermedia: 8 years' follow-up in Egypt.
    El-Beshlawy A, El-Ghamrawy M, EL-Ela MA, Said F, Adolf S, Abdel-Razek AR, Magdy RI, Abdel-Salam A.
    Ann Hematol; 2014 Dec 18; 93(12):2045-50. PubMed ID: 25062719
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Curcuminoids supplementation ameliorates iron overload, oxidative stress, hypercoagulability, and inflammation in non-transfusion-dependent β-thalassemia/Hb E patients.
    Hatairaktham S, Masaratana P, Hantaweepant C, Srisawat C, Sirivatanauksorn V, Siritanaratkul N, Panichkul N, Kalpravidh RW.
    Ann Hematol; 2021 Apr 18; 100(4):891-901. PubMed ID: 33388858
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Thalidomide and Hydroxyurea in Transfusion-Dependent Thalassemia: Efficacy, Safety Profile and Impact on Quality of Life.
    Bhattacharjee S, Ghosh S, Shaw J, Bhattacharjee S, Bhattacharyya M.
    Hemoglobin; 2024 May 18; 48(3):161-168. PubMed ID: 39092801
    [Abstract] [Full Text] [Related]

  • 12. Iron overload in non-transfusion-dependent thalassemia: association with genotype and clinical risk factors.
    Tantiworawit A, Charoenkwan P, Hantrakool S, Choeyprasert W, Sivasomboon C, Sanguansermsri T.
    Int J Hematol; 2016 Jun 18; 103(6):643-8. PubMed ID: 27052211
    [Abstract] [Full Text] [Related]

  • 13. Improved efficacy and tolerability of oral deferasirox by twice-daily dosing for patients with transfusion-dependent β-thalassemia.
    Chang HH, Lu MY, Liao YM, Lin PC, Yang YL, Lin DT, Chiou SS, Jou ST, Lin KH, Chang TT.
    Pediatr Blood Cancer; 2011 Mar 18; 56(3):420-4. PubMed ID: 21072825
    [Abstract] [Full Text] [Related]

  • 14. Oral isobutyramide reduces transfusion requirements in some patients with homozygous beta-thalassemia.
    Reich S, Bührer C, Henze G, Ohlendorf D, Mesche M, Sinha P, Kage A, Müller C, Vetter B, Kulozik AE.
    Blood; 2000 Nov 15; 96(10):3357-63. PubMed ID: 11071627
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Time to Start Delivering Iron Chelation Therapy in Newly Diagnosed Severe β-Thalassemia.
    Susanah S, Idjradinata PS, Sari NM, Rakhmilla LE, Sribudiani Y, Trisaputra JO, Moestopo O.
    Biomed Res Int; 2020 Nov 15; 2020():8185016. PubMed ID: 33415156
    [Abstract] [Full Text] [Related]

  • 17. The Long-Term Efficacy of Deferiprone in Thalassemia Patients With Iron Overload: Real-World Data from the Registry Database.
    Kittipoom T, Tantiworawit A, Punnachet T, Hantrakun N, Piriyakhuntorn P, Rattanathammethee T, Hantrakool S, Chai-Adisaksopha C, Rattarittamrong E, Norasetthada L, Fanhchaksai K, Charoenkwan P.
    Hemoglobin; 2022 Mar 15; 46(2):75-80. PubMed ID: 35982534
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Common fetal hemoglobin variants in Lebanese patients bearing the codon 29 beta gene mutation associated with different thalassemia phenotypes.
    Brancaleoni V, Moukhadder HM, Consonni D, Koussa S, Di Pierro E, Cappellini MD, Taher A.
    Ann Hematol; 2019 Apr 15; 98(4):833-840. PubMed ID: 30506348
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.